Senzime AB (publ) (SEZI) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Pleasure to be here. I'm here to present Sanzime Q4 2025 results, as well as a brief summary of the year of 2025. So if we start by looking at overall 2025, it was a year of continued accelerated growth, and we took clear continued steps towards profitability. We grew about 90% in constant currencies. So we met the guidance of reaching above 110 million in constant currencies. Our underlying gross margin increased. Our OPEX remained stable and our adjusted EBITDA improved by about 60%. So the fundamentals are there. We're really reconfirming our goal to reach positive cash flow during 2026. And this is going to be fueled by continued growth and stringent cost control. So this was a summary. I'll dig down deeper into the numbers. If we look at Q4 alone, it was a strong ending to the year. We more than doubled the business. We reached 28.3 million SEIC in reported revenues and 31.2 if you're looking at the constant currencies. The growth was driven by more important hospital wins, very strong sensor growth. We had more guidelines coming in that I'll dig deeper into. And we had an exciting regulatory approval in Japan that started kicking off the next gen. And it was also a quarter of launching additional new products. We came out with the Mgen software suite that I will talk a little bit more about. So if you look at our installed base of tetragraphs and the shipments we're doing, it keeps on growing. Throughout the year, we shipped out 2,139 tetragraphs, predominantly the next-gen tetragraph, comparable to just under 900 the year before. So strong growth. If we look at Q4 standalone, it was 416 units. It's notable that some of these units, a few hundred, are hospitals that have upgraded from the older platform to our new next generation platform. Hence, ...